Reference : Group B Streptococcus neonatal invasive infections in Belgium, 2013-2016
Scientific congresses and symposiums : Paper published in a book
Human health sciences : Public health, health care sciences & services
Human health sciences : Pediatrics
Human health sciences : Immunology & infectious disease
Human health sciences : Laboratory medicine & medical technology
http://hdl.handle.net/2268/223201
Group B Streptococcus neonatal invasive infections in Belgium, 2013-2016
English
MELIN, Pierrette mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service de microbiologie clinique >]
LECOMTE, Laurie []
SACHELI, Rosalie mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service de microbiologie clinique >]
DESCY, Julie mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service de microbiologie clinique >]
HUYNEN, Pascale mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service de microbiologie clinique >]
HAYETTE, Marie-Pierre mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service de microbiologie clinique >]
MEEX, Cécile mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service de microbiologie clinique >]
2018
Abstract book of 1st ISSAD 2018
Yes
International
1st International Symposium on Streptococcus agalactiae Disease (ISSAD)
20th – 23rd February 2018
Bill & Melinda Gates foundation
W.H.O.
Cape Town
South Africa
[en] Group B streptococcus ; Neonatal invasive disease ; Belgium
[en] Background
Since 2003, intrapartum antimicrobialprophylaxis (IAP) based on a universal screening for group B streptococcus (GBS) colonization at 35-37 weeks’ gestation is recommended in Belgium. Following, a decrease in the incidence of early-onset disease (EOD) was observed whereas late onset disease (LOD) have not changed. We describe the clinical and bacteriological characteristics of GBS neonatal invasive infections reported to the Belgian National Reference Centre (NRC) for GBS from 2013 to mid 2016.
Methods
On a voluntary base, all laboratories located in Belgium are invited to notify GBS neonatal invasive disease to the NRC, to send the isolate and fill a case-report questionnaire. This surveillance includes cases from 01.2013 to 07.2016. Following confirmation of identification, capsular-typing was performed by both agglutination and with PCR.
Results
Data from 157 GBS invasive neonatal cases were analysed: according to age at onset there were 70 EOD (median: day 0) and 57 LOD (median: 28 days). Among EOD cases, a male/female ratio was 0.75. The major types were III (35.7%), followed by Ia, II, V, Ib, IV, VI (20%, 14.3%, 12.9%, 10%, <10%). Fever and respiratory distress were frequently reported at onset. Meningitis was notified for 10,7% of cases. Among LOD cases, male/female ratio was 0.86. The predominant type was III (71.6%), followed mainly by Ia (13.4%). Gestational age at birth was significantly lower for LO cases and twins more frequent. The predominant characteristic at onset was fever and 32.5% developed meningitis. One death was reported in both groups of EOD and LOD. Antenatal GBS screening results and IAP were also analysed in regard to age at onset of diseases.
Conclusions
Clinical presentations were associated with age at onset of infection. Serotype III predominated in neonatal infections. Positive antenatal screening and appropriate IAP were not always protective for EOD and of course not for LOD.
CIRM
The national reference centre is partially supported by the Belgian Ministry of Social Affairs through a fund within the health insurance system
Researchers ; Professionals
http://hdl.handle.net/2268/223201

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
ISSAD 2018 poster clinical GBS neonatal disease.pdfPublisher postprint189.45 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.